CV: Myocardial Infarction Societal cost 6M emergency room visits/year(US); 2.5M admitted to critical care unit 34K sent home improperly Genomic Lipoprotein a(positive Scan/PHarma Therapy prognosIs · Targeted SPECT agent · Thrombolytic to ⅣvD (apoptosis and cellular restore blood flow (negative prognosis · Platelet activation and viability measure to affected tissue fibrinogen metrics ·Eva| uation of viab|ev Anti-apoptotic Suggest plaque rupture, necrotic v pre-apoptoti agent(caspase-3 fissure and thrombosis heart tissue and inhibitor )to allow hemorrhage potential pre-apoptotic recovery Symptomology Angina(chest pain) Standard blood gas erapy Evaluation electrolyte and blood chemistry measures Genomics and Molecular i magi nG e n o m i c s a n d M o l e c u l a r I m a g i n g CV: Myocardial Infarction Societal Cost 6M emergency room visits/year (US); 2.5M admitted to critical care unit 34K sent home improperly Genomic • Lipoprotein A (positive prognosis) • C-reactive protein (negative prognosis) Symptomology • Angina (chest pain) • Standard blood gas, electrolyte and blood chemistry measures IVD • Platelet activation and fibrinogen metrics • Suggest plaque rupture, fissure and thrombosis Scan/DPharma • Targeted SPECT agent (apoptosis) and cellular viability measure • Evaluation of viable v necrotic v pre-apoptotic heart tissue and hemorrhage potential Therapy • Thrombolytic to restore blood flow to affected tissue • Anti-apoptotic agent (caspase-3 inhibitor) to allow pre-apoptotic recovery Therapy Evaluation N N NH O O